What Flynn Pharma does

Flynn Pharma is a privately held pharmaceutical company founded in 1994 and headquartered in Stevenage, England. The company develops, supplies, and distributes branded and generic medicines across six therapy areas: psychiatry, paediatrics, anti-infective medicine, women's health, gastroenterology, and emergency medicine. Its core commercial thesis is to re-discover and re-energise established drugs — introducing new products, improving existing formulations, and adding new indications to extend the value of its portfolio. Geographic operations span the United Kingdom and the Republic of Ireland, with a wholly owned German subsidiary (Inresa) and a UK affiliate (MicroPharm) forming the broader corporate family.

The company sells primarily through UK-based Contract Sales Organisations (CSOs) that engage NHS clinicians, pharmacists, and prescribers, with products distributed via pharmacy and dispensing channels. Flynn Pharma also operates an in-licensing proposition for companies seeking entry into the UK or EU pharmaceutical markets, offering branded campaign capabilities across primary care, secondary care, and specialist medicine. Its principal digital asset is the Flynn Forum platform — a healthcare-professional-only site hosting CPD-certified events, clinical tools, education, and patient support materials segmented into three communities: Neurodevelopmental Disorders, Women's Health, and General Medicine. The business is privately held with no parent company, no disclosed institutional investors, and no publicly filed revenue data.

Name

Flynn Pharma

Legal name

Flynn Pharma Limited

Website

https://flynnpharma.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

11–50 employees

Short description

Flynn Pharma is a privately held UK pharmaceutical company, founded 1994, that supplies branded and generic medicines across psychiatry, paediatrics, women's health, gastroenterology, anti-infective, and emergency medicine to the UK and Irish healthcare markets via CSO-led sales.

Ownership category

akta.pro rank

Product category

Pharmaceutical Products (Branded and Generic Medicines)

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Branded pharmaceuticals
• Generic medicines
• Prescription drug supply
• Women's health therapeutics
• Neurodevelopmental disorder drugs

Headquarters

HQ city

Stevenage

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Marketing or Sales, Operations, Personnel, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Flynn Pharma generates revenue through the sale of branded and generic medicines across multiple therapy areas including psychiatry, paediatrics, anti-infective medicine, women's health, gastroenterology and emergency medicine. The company introduces new products, improves existing formulations, and adds new indications to their product portfolio.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Flynn Pharma develops, supplies, and distributes branded and generic pharmaceutical medicines across multiple therapy areas including psychiatry, paediatrics, anti-infective medicine, women's health, gastroenterology, and emergency medicine. The company re-discovers and re-energises established drugs, introduces new products, improves existing formulations, and adds new indications. It also operates the Flynn Forum platform, a dedicated digital resource for UK healthcare professionals.

Product overview

Flynn Pharma is a privately held pharmaceutical company engaged in developing, introducing, and supplying branded and generic medicines. The company operates across multiple therapy areas including psychiatry, paediatrics, anti-infective medicine, women's health, gastroenterology, and emergency medicine. Flynn Pharma's core digital product is the Flynn Forum platform, which comprises three distinct community sub-brands (NDD Community, Women's Health Community, and General Medicine Community) providing therapy-specific resources, events, and product information for UK healthcare professionals. The company also maintains external product listings for its medicines across the UK and Republic of Ireland markets.

Differentiator

Problem solved

Functional benefit

Products and services

• Flynn Forum A digital platform for UK healthcare professionals hosting education, training, resources, events, and product information across neurodevelopmental disorders (NDD), women's health, and general medicine. The platform contains clinical tools and patient support materials to help with consultations in each community.
• Flynn Pharma Medicines (United Kingdom) Flynn Pharma's portfolio of branded and generic medicines supplied in the UK market, covering therapy areas including psychiatry, paediatrics, anti-infective medicine, women's health, gastroenterology and emergency medicine.
• Flynn Pharma Medicines (Republic of Ireland) Flynn Pharma's portfolio of branded and generic medicines supplied in the Republic of Ireland market, covering the same multi-therapy area range as the UK portfolio.
• Pharmaceutical In-Licensing Partnerships (UK/EU) An in-licensing partnership offering for pharmaceutical companies seeking to enter the UK or EU markets, providing Flynn Pharma's regulatory infrastructure, sales capabilities, and branded campaign execution across key therapy areas.

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core and minor.

• Companies seeking UK/EU market entrycoreStrategic or Co-development PartnerFlynn Pharma operates as a dynamic and responsible in-licensing partner for companies interested in successfully entering the UK or EU pharmaceutical markets. They have significant experience and capability in creating and implementing compelling branded campaigns that deliver industry leading results in key therapy areas. Their commitment to collaboration enables delivery of value to patients, healthcare professionals and partners across primary care, secondary care, and specialist medicine.
• MicroPharmminorOthersMember of the Flynn Pharma family of companies. MicroPharm is listed as another group company alongside Flynn Pharma.
• InresaminorOthersMember of the Flynn Pharma family of companies. Inresa is based in Germany and listed as another group company alongside Flynn Pharma.
• NHS Leaders and Third Sector OrganisationsminorStrategic or Co-development PartnerFlynn Pharma develops patient-focused resources and materials designed to improve decision-making and support service improvement across multiple therapy areas. These are developed in collaboration with clinicians, NHS leaders and the third sector.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Aspen Pharmacare Holdings: Global generics and specialty pharma with established European branded-generic operations — comparable as a broader incumbent operating Flynn's same commercial model at much larger scale across multiple regions.
• Amneal Pharmaceuticals: US-headquartered but with growing European footprint, focused on affordable generics and specialty branded products across CNS, women's health and other therapy areas overlapping with Flynn.
• Teva Pharmaceutical Industries: World's largest generic medicines manufacturer with a deep UK/European presence, supplying many of the same pharmacy and NHS channels that Flynn targets — a broader incumbent competing in the same distribution layer.
• Viatris (formerly Mylan): Global generics and branded pharma with major UK operations, competing for the same NHS tenders and pharmacy distribution slots that Flynn depends on for revenue.
• Zentiva Group: European generics and specialty pharma headquartered in Prague with strong UK/Ireland distribution — overlapping with Flynn in branded-generic distribution to pharmacies and NHS customers.

Direct peers

• Theramex: Women's-health focused specialty pharma with a UK and European footprint, addressing menopause, contraception and similar indications that overlap directly with Flynn's Women's Health Community portfolio.
• Alliance Pharma plc: UK-listed specialty pharma that acquires, markets and distributes established branded prescription and consumer healthcare products across multiple therapy areas — closely matching Flynn's branded/generic re-energisation model and UK/European distribution focus.
• Consilient Health: Privately held UK and Ireland pharma company marketing branded generic and specialty medicines across women's health, CNS, and other therapy areas — directly comparable in scale, geography, and therapy mix to Flynn Pharma.
• Galen (Galen Limited): Northern Ireland-headquartered pharma focused on branded generics and established molecules across women's health, pain and CNS — operating in similar UK/Irish markets with a comparable branded-generic commercialisation model.

Emerging players

• Stragen Pharma: Smaller specialty pharma focused on women's health and niche indications with European distribution, comparable to Flynn's therapeutic-area focus but at a smaller scale and different geographic centre of gravity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/flynn-pharma-limited

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flynn Pharma